Form 4: Denali Therapeutics CEO Ryan J. Watts Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Denali Therapeutics CEO Ryan J. Watts sold 2,260 shares of common stock on August 20, 2024, to satisfy tax obligations related to the settlement of previously vested restricted stock units.
Summary
- On August 20, 2024, Ryan J. Watts, the President and CEO of Denali Therapeutics Inc., sold 2,260 shares of the company's common stock.
- The sale was executed at a price of $23.79 per share.
- This transaction was conducted to cover tax obligations arising from the settlement of previously vested restricted stock units (RSUs).
- Following the transaction, Watts directly owns 235,807 shares of Denali Therapeutics, which includes 197,200 unvested RSUs.
- Watts also indirectly owns 2,202,604 shares through the Watts Family 2015 Trust, for which he serves as trustee.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting a transaction. The sale is for tax purposes, which is a common occurrence. Therefore, the sentiment is moderately neutral.
Industry Context
Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company insiders. This sale is related to tax obligations and may not reflect a change in the executive's long-term outlook for the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| July 7, 2015 | Date of the Watts Family 2015 Trust |
| August 20, 2024 | Date of stock sale transaction |
| August 22, 2024 | Date of signature by power of attorney |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.